Literature DB >> 31216968

Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke.

Markus Kneihsl1, Thomas Gattringer1, Egbert Bisping2, Daniel Scherr2, Reinhard Raggam3, Harald Mangge4, Christian Enzinger1, Simon Fandler-Höfler1, Sebastian Eppinger1, Christina Hermetter1, Bernd Bucnik1, Birgit Poltrum1, Kurt Niederkorn1, Franz Fazekas1.   

Abstract

Background and Purpose- Occult atrial fibrillation (AF) causes a relevant proportion of initially cryptogenic stroke (CS), but prolonged rhythm monitoring is difficult to apply to all such patients. We hypothesized that blood biomarkers indicating heart failure (NT-proBNP [N-terminal pro-brain natriuretic peptide]) and hypercoagulability (D-dimer, AT-III [antithrombin-III]) were associated with AF-related stroke and could serve to predict the likelihood of AF detection in CS patients early on. Methods- Over a 1-year period, we prospectively applied a defined etiologic work-up to all ischemic stroke patients admitted to our stroke unit. If no clear stroke cause was detected (CS), patients underwent extended in-hospital cardiac rhythm monitoring (≥72 hours). Blood to determine biomarker levels was drawn within 24 hours after admission. Results- Of 429 patients, 103 had AF-related stroke. Compared with noncardiac stroke patients (n=171), they had higher NT-proBNP (1867 versus 263 pg/ml) and D-dimer levels (1.1 versus 0.6 µg/ml), and lower AT-III concentration (89% versus 94%). NT-proBNP ≥505 pg/ml distinguished AF-related from noncardiac stroke with a sensitivity of 93% and a specificity of 72%. D-dimer and AT-III cutoffs had lower sensitivities (61% and 53%) and specificities (58% and 69%) for AF-related stroke. Of all initially 143 CS patients, 14 were diagnosed with AF during in-hospital monitoring. The preidentified NT-proBNP cutoff ≥505 pg/ml correctly predicted AF in 12 of them (86%, negative predictive value: 98%), while D-dimer and AT-III cutoffs were noncontributory. Conclusions- This study supports the association of NT-proBNP and to a lesser extent of hypercoagulation markers with AF-related stroke. NT-proBNP seems helpful in selecting CS patients for immediate extended cardiac rhythm monitoring to detect occult AF whereby levels <505 pg/ml seem to have a high-negative predictive value.

Entities:  

Keywords:  D-dimer; N-terminal pro-brain natriuretic peptide; antithrombin III; atrial fibrillation; biomarkers; heart failure; stroke

Year:  2019        PMID: 31216968     DOI: 10.1161/STROKEAHA.119.025339

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study.

Authors:  Markus Kneihsl; Egbert Bisping; Daniel Scherr; Harald Mangge; Simon Fandler-Höfler; Isabella Colonna; Melanie Haidegger; Sebastian Eppinger; Edith Hofer; Franz Fazekas; Christian Enzinger; Thomas Gattringer
Journal:  Eur J Neurol       Date:  2021-09-23       Impact factor: 6.288

2.  Soluble fibrin monomer complex as a candidate sentinel for adverse events in patients with heart failure.

Authors:  Anke C Fender; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2021-01-09

3.  Atrial fibrillation: villain or bystander in vascular brain injury.

Authors:  Ben Freedman; Hooman Kamel; Isabelle C Van Gelder; Renate B Schnabel
Journal:  Eur Heart J Suppl       Date:  2020-12-06       Impact factor: 1.803

4.  Liver Fibrosis-4 index indicates atrial fibrillation in acute ischemic stroke.

Authors:  Simon Fandler-Höfler; Markus Kneihsl; Rudolf E Stauber; Egbert Bisping; Harald Mangge; Gerit Wünsch; Melanie Haidegger; Linda Fabisch; Isra Hatab; Peter Fickert; David Werring; Christian Enzinger; Thomas Gattringer
Journal:  Eur J Neurol       Date:  2022-05-24       Impact factor: 6.288

5.  It's Time to Say Goodbye to the ESUS Construct.

Authors:  Blanca Fuentes; Raquel Gutiérrez-Zúñiga; Exuperio Díez-Tejedor
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.